Pancreatitis signal

What is known

• Acute pancreatitis events occur in trials of GLP-1 RAs, with low absolute incidence.
• Major meta-analyses have not consistently established a class-wide causal increase versus placebo.
• Personal or family history of pancreatitis is a contraindication or specific warning in the licensed SmPCs for the major agents (semaglutide, liraglutide, dulaglutide, tirzepatide).
• SmPC guidance is that GLP-1 therapy should be discontinued if pancreatitis is suspected, and not restarted if confirmed.

What remains uncertain

• Whether the signal is mechanistic, confounded by underlying obesity/T2D risk, or both.
• Risk gradient across newer molecules (tirzepatide, retatrutide) compared with older agents.
• How to individually risk-stratify patients with remote (e.g., gallstone-related) pancreatitis history vs recurrent-idiopathic pancreatitis vs first-degree relative with pancreatitis — the SmPCs treat these categorically but individual risk profiles differ.
• Whether recovery time since a single prior pancreatitis episode meaningfully modifies future risk under GLP-1 therapy.

Trial limitations

• Phase 3 trials are not powered for rare adverse events.
• Population enrichment toward T2D may shift baseline pancreatitis risk and complicate attribution.
• Patients with prior pancreatitis are excluded from most pivotal trials, so trial data cannot inform risk in the population most affected by the contraindication.

FAQs

Can I take a GLP-1 medicine if I had pancreatitis in the past?

The licensed SmPCs for semaglutide, liraglutide, dulaglutide and tirzepatide list a personal history of pancreatitis as a contraindication or specific warning. Any consideration of GLP-1 therapy in this situation is a specialist prescriber judgement that weighs the individual's risk profile (single vs recurrent episodes, cause, time since resolution, current pancreatic function) against the expected benefit. This is not a self-management decision.

Does family history of pancreatitis matter?

The SmPCs primarily focus on personal history rather than family history. However, family history of hereditary or recurrent pancreatitis may indicate an underlying inherited susceptibility that a prescriber will want to factor into risk assessment. Discuss any relevant family history with your prescriber before starting therapy.

How much time since a prior episode reduces the risk?

The evidence base does not establish a specific time-since-episode threshold. The SmPC contraindication is categorical rather than time-dependent. Prescribers considering therapy in individuals with a remote, single, resolved episode (e.g., gallstone pancreatitis from many years ago) may reach different conclusions from those considering recurrent-idiopathic pancreatitis — but this is a clinical judgement, not a rule.

What should I do if I develop severe abdominal pain while on therapy?

Severe upper-abdominal pain, especially radiating to the back, with nausea or vomiting, is a red-flag symptom that warrants urgent qualified clinical assessment. The SmPCs indicate that GLP-1 therapy should be discontinued if pancreatitis is suspected and not restarted if confirmed. Suspected cases should also be reported to MHRA via the Yellow Card scheme.